Login or register (free and only takes a few minutes) to participate in this question.You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.
English to German translations [PRO]
Medical - Medical: Pharmaceuticals / Arzneimittelstudie (Brustkrebs) | | English term or phrase: baseline neuropathy | Subjects to be excluded
1. Known hypersensitivity to paclitaxel or to any other component of the paclitaxel formulation (see Appendix C)
2. Pregnant or lactating women; all fertile subjects must use effective contraception (barrier method) while on study and for 3 months thereafter. All subjects must agree to use a highly effective method of contraception (including their partner). Effective birth control includes (a) IUD plus 1 barrier method, or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm.) Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.
3. Subjects with symptomatic CNS metastases. Subjects with treated brain metastases that have remained stable for at least 3 months without steroids are allowed. Subjects with signs or symptoms or history of brain metastasis must have a CT or MRI scan of the brain within 1 month prior to the start of protocol therapy. Subjects with spinal cord or nerve root compression who have completed treatment at least 4 weeks before the start of protocol therapy and are stable without steroid treatment for at least one week before start of protocol therapy are allowed. Subjects with leptomeningeal metastases are not allowed.
4. Any of the following hematologic abnormalities:
• Hemoglobin < 9.0 g/dL
• ANC < 1500 per mm3
• Platelet count < 100,000 per mm3
5. Any of the following serum chemistry abnormalities:
• Total bilirubin > 1.5 × ULN (>2.5 mg/dL in patients with Gilbert’s syndrome)
• AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)
• GGT > 2.5 x ULN (or > 5 × ULN for subjects with liver metastasis)
• Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis)
• Serum albumin < 3.0 g/dL
• Serum creatinine > 1.5 × ULN
• Proteinuria > 2.5 g/24 hours or 3+ with urine dipstick
• Any other ³ Grade 3 laboratory abnormality at baseline (other than those listed above)
6. Significant cardiovascular disease, including:
• Clinically symptomatic heart failure. Subjects with a history of heart failure must have an ECHO or MUGA scan to document left ventricular ejection fraction (LVEF) > 45% prior to start of protocol therapy
• Uncontrolled hypertension: Blood pressure >140/90 mm Hg on more than 2 antihypertensive medications, on two consecutive measurements obtained at least 24 hours apart. Subjects with a history of hypertension must have been on stable doses of anti-hypertensive drugs for ≥ 2 weeks prior to start of protocol therapy.
• Myocardial infarction within 3 months prior to start of protocol therapy
7. ***Baseline neuropathy*** > Grade 1
8. Subjects with delayed healing of wounds, ulcers, and/or bone fractures |
| | | Selected response from:
  Harald Moelzer (medical-translator)
Germany
Local time: 06:58
| Grading comment Danke Harald et al.
4 KudoZ points were awarded for this answer |
| |
| Discussion entries: 0 |
|---|
Automatic update in 00:
|
3 hrs confidence:   peer agreement (net): +9 Neuropathie (> Grad 1) vor/zu Beginn der Studie
Explanation:
...oder auch:
"Neuropathie (> Grad 1) als Ausgangsbefund"
...
| | | |
|
| |
The translation workplace 
